Seventure Partners’ Post

Learn how MasterControl helps Navigate BioPharma achieve their goals. https://ow.ly/HY6L50Qkrc4

Learn how MasterControl helps Navigate BioPharma achieve their goals. https://ow.ly/Xv1k50Qkr9p

Learn how MasterControl helps Navigate BioPharma achieve their goals. https://ow.ly/wJFV50QkraT

First vs. Best in Class — Simplifying the Equation for Biopharma A classic question that frequently comes back. Nice report from L.E.K. Consulting covering this topic. https://lnkd.in/eJH8mdsn

What will 2024 bring to the biopharma industry? Will the tightening of available financing continue, and what will its impact be on valuations, deal structure and partnerships? Will the CGT industry buckle the trends and expectations? Biopharma experts and executives share their outlook and expectations for this year.

'Scrip Asks' is a series we do every year, forecasting what lies in the year ahead, with industry feedback and our own insights. This year too Eleanor Malone brings these insightful pieces, which we are told many in the industry look forward to #biotech #pharmaceutical #forecasts #2024trends #2024opportunities #2024outlook

In your investor deck, emphasize the in vivo efficacy of your compound compared to the standard of care. Demonstrating that your drug works is not sufficient; proving its superiority over existing market options is crucial.

For those who don't know – my team at Real Chemistry publishes Value Report, a weekly newsletter sharing news and insights on all things drug pricing and access. In our last issue of 2023, my colleagues and I (at the direction of our fearless leader Andrew) came together to share reflections on the past year or a projection of the year ahead. Naturally, mine had to give nod to what could lie ahead in relation to #ESG and #sustainability. "In 2024, I foresee a stronger thread between pharma companies’ drug pricing and access decisions and the expectations from stakeholders set by sustainability guidelines. Access to medicine is a material issue for the sustainability efforts of drug manufacturers. With the topic of drug pricing so prominent in the political landscape, we could see an influx of companies leaning into the calls for transparency, leveraging its reporting requirements as a communications tool to broadcast corporate responsibility efforts. I expect companies will also continue to educate about the role of health system players – drug companies, insurers, PBMs, etc. – in ensuring patients around the world can access needed medicines." Nothing like kicking off the new year with some self promotion. 😄 Sign up for Value Report for free below!

Did you know: for one leading #pharmaceutical company, frequent recognition correlated with 15% lower #turnover and was found to be 8x more powerful than salary increases in improving #engagement? 🤯 In this paper, @Workhuman takes a closer look at how when #recognition is done right, it drives unmatched results for the biopharma workforce.

Leaders in biopharma, let's explore how our Global Biopharma Resilience Index can help you chart a path to enhanced resilience. Discover four recommendations for how to strengthen our industry in the face of talent shortages, regulatory complexity, and economic uncertainty. Read the article for more information: https://lnkd.in/eN5ayciE #biopharma #innovation #lifesciences #drugdevelopment